A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.
• Participants must be willing and able to give written informed consent, adhere to trial procedures and able to read and understand English.
• Male and female participants 18 to 65 years of age.
• Participants must possess a smartphone and is familiar with its use and is willing to download and interact with the Abilify MyCite® app. Participants with a smartphone, that is not compatible with the Abilify MyCite® app will be offered a loaner phone for the trial period.
• Clinical diagnosis of schizophrenia and able to ingest oral medication.
• Positive and Negative Syndrome Scale (PANSS) total score between 60-90.
• Participants currently prescribed oral atypical antipsychotic medication including aripiprazole or appropriate for aripiprazole treatment for 6 months or longer.
• Participants are required to have had an inpatient hospitalization for schizophrenia within the last 48 months prior to entering the trial.
• Skin on the anterior chest just above the lower edge of the rib cage that is free of any dermatological problems.